Leerink Partners Announces Innovative Therapeutics Research Model

Leerink Partners, a leading healthcare investment bank, announced today
the completion of hiring for their new disease-focused Therapeutics
Research team. The novel alignment by therapeutic area will allow
research analysts to develop and maintain expertise in their respective
areas; Mr. Schwartz (Rare Diseases), Dr. Foroohar (Genetic Medicines),
Dr. Sarraf (Inflammation and Immunology), Mr. Goodman (Neurosciences),
Dr. Graybosch (Immuno-oncology), Dr. Berens (Targeted Oncology), Dr.
Chang (Emerging Oncology), Ms. Fadia (Women’s Health, Pain and Generics)
and Dr. Porges (Diversified Biopharma).

This follows recent hiring announcements of five therapeutics analysts
in the second quarter of 2018. The Therapeutics Research team is charged
with elevating the firm’s therapeutics research coverage to be the
deepest and broadest effort on the street. The expanded team is expected
to cover over 180 companies to support the firm’s growing list of
biopharmaceutical relationships.

“We are excited to have completed the build-out of our Therapeutics
Research team,” commented Jeff Leerink, Chairman and CEO of Leerink
Partners. “This further specialization reinforces our commitment to
being the most knowledgeable research provider on the street.”

“Leerink’s Equity Research team has a demonstrated history of delivering
unique and valuable insights to investors across every sector of
healthcare,” stated John Sullivan, CFA, Senior Managing Director of
Equity Research and Healthcare Investment Strategist at Leerink
Partners. “This exceptional group of analysts has the resources and
experience to fulfill our ambitious goals for our therapeutics research

Geoffrey Porges, MBBS, Director of Therapeutics Research at Leerink
Partners added, “As the biopharmaceutical industry rapidly evolves, and
new products and technologies emerge at an accelerating pace, our
disease -focused Therapeutics Research team will keep abreast of those
changes and developments. Their focused attention and personal expertise
should provide meaningful insights concerning even the most technically
complex products, markets and stocks in the sector.”

About Leerink Partners

Leerink Partners LLC is a leading investment bank, specializing in
healthcare. Our knowledge, experience and focus enable us to help our
clients define and achieve their strategic, capital markets and
investment objectives. We partner with companies that develop and
commercialize innovative products and services that are defining the
future of healthcare. Leerink Partners LLC is a member of FINRA/SIPC.
For more information, please visit: www.leerink.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180618005308/en/